Related Experiment Videos
Low dose prednisolone in nephrotic syndrome
I A Choonara1, D Heney, S R Meadow
1Department of Paediatrics and Child Health, St James's University Hospital, Leeds.
Archives of Disease in Childhood
|April 1, 1989
Summary
Low-dose prednisolone effectively treats steroid-responsive nephrotic syndrome, inducing remission in all patients within 14 days. This dosage also maintained remission duration similarly in patients with prior relapse history.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
Background:
- Nephrotic syndrome is a common kidney disorder in children.
- Steroid-responsive nephrotic syndrome (SRNS) typically requires corticosteroid treatment.
- Optimizing prednisolone dosage for sustained remission is crucial.
Purpose of the Study:
- To evaluate the efficacy of a low-dose prednisolone regimen in inducing remission of SRNS.
- To compare remission duration in patients treated with low-dose prednisolone, including those with prior relapse history.
Main Methods:
- A cohort of 16 patients with SRNS received low-dose prednisolone (30 mg/m2/day) over 29 treatment occasions.
- Remission was defined by clinical and biochemical parameters.
- Remission duration was analyzed, comparing patients with and without prior relapse history.
Main Results:
- All patients achieved remission within 14 days of initiating low-dose prednisolone.
- The duration of remission was comparable between patients who had previously relapsed and those who had not.
- Low-dose prednisolone demonstrated consistent efficacy in inducing and maintaining remission.
Conclusions:
- Low-dose prednisolone (30 mg/m2/day) is an effective treatment for inducing remission in SRNS.
- This regimen appears to provide a similar duration of remission, even in patients with a history of relapses.
- Further research may explore long-term outcomes and optimal dosing strategies.